重症医学中的侵袭性念珠菌病:塑造诊断与治疗的未来
该文由重症医学科、感染病科、临床微生物和药学专家共同撰写的当代多学科叙述性综述,聚焦ICU成人侵袭性念珠菌病的诊断与治疗。综述指出血培养敏感性持续有限(约40%),非培养检测如β-D-葡聚糖和分子诊断可更快检出且阴性预测值高,但阳性预测值低且临床采用不一致;缺乏经验证的宿主源性生物标志物限制了风险分层和抗真菌停药决策。结论强调新型抗真菌药物、抗真菌药物管理策略和多学科诊疗模式对改善预后和减少耐药至关重要,需整合团队诊疗以弥合持续存在的管理差距。
要点
- 血培养诊断侵袭性念珠菌病敏感性持续有限,仅约40%,阴性不能排除。
- β-D-葡聚糖和分子诊断阴性预测值高、阳性预测值低,临床采用不一致。
- 缺乏经验证的宿主源性生物标志物,限制风险分层、抗真菌停药决策和个体化诊疗。
- 治疗成功同等依赖及时准确诊断和基于临床情境的个体化治疗。
- 新型抗真菌药物、抗真菌药物管理策略和多学科诊疗模式对改善预后和减少耐药至关重要。
适用人群与场景
- ICU危重成人患者,聚焦侵袭性念珠菌病;综述排除非侵袭性念珠菌病真菌感染和非ICU患者人群。
处置流程与药物剂量
- 治疗成功取决于及时准确诊断和个体化、基于临床情境的治疗。
- 抗真菌药物管理策略和多学科团队诊疗模式是改善预后和减少耐药的关键。
- 新兴抗真菌药物是改善临床结局和减少耐药的要素之一。
研究设计与关键结果
- 多学科叙述性综述,由重症医学科、感染病科、临床微生物学和药理学专家撰写,聚焦ICU侵袭性念珠菌病。
- 血培养诊断敏感性持续有限,约40%。
- 非培养检测包括β-D-葡聚糖和分子诊断,可更快检出且阴性预测值高,但阳性预测值低且临床采用不一致。
- 缺乏经验证的宿主源性生物标志物,限制风险分层、抗真菌停药决策和个体化诊疗。
- 结论强调新兴抗真菌药物、管理策略和多学科诊疗模式对改善临床结局和减少耐药至关重要。
证据类型、等级与局限
- 证据类型:多学科叙述性综述;方法为批判性回顾相关文献和专家共识,未报告系统检索策略或证据分级体系。
- 局限:原文未报告局限性
对床旁实践的改变
- 血培养阴性不能排除侵袭性念珠菌病,因敏感性约40%。
- 使用β-D-葡聚糖和分子诊断时需注意其阳性预测值低,结果解读应结合临床。
- 缺乏经验证的宿主源性生物标志物,抗真菌停药决策和风险分层不能仅依赖单一标志物。
- 作者认为新兴抗真菌药物、抗真菌药物管理策略和多学科诊疗模式对改善预后和减少耐药至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Invasive candidiasis (IC) remains one of the most challenging infections in critical care, contributing significantly to morbidity, prolonged organ support, and mortality among intensive care unit (ICU) patients. The clinical landscape of IC is evolving, with increasing recognition of Candida non-albicans species and other yeasts formerly classified as Candida spp., alongside emerging multidrug resistance and growing complexity in host immune profiles.
OBJECTIVES: This contemporary, multidisciplinary narrative review-authored by intensivists, infectious diseases specialists, clinical microbiologists, and pharmacologists-aims to provide ICU clinicians with practical, up-to-date insights into the diagnosis and management of IC. To maintain clinical focus, the review excludes non-IC fungal infections and non-ICU patient populations.
METHODS: Relevant literature and expert consensus were critically reviewed to summarize current diagnostic and therapeutic approaches for IC in critically ill patients. Emphasis was placed on pragmatic clinical application, diagnostic limitations, antifungal stewardship, and personalized therapeutic decision-making.
RESULTS: Despite the availability of novel antifungal agents with improved pharmacokinetic properties, treatment success in IC depends equally on timely and accurate diagnosis and individualized, context-aware therapy. Blood cultures continue to demonstrate limited sensitivity (~40%). Non-culture assays, including β-D-glucan and molecular diagnostics, provide faster detection and high negative predictive value but suffer from low positive predictive value and inconsistent adoption in clinical practice. The absence of validated host-derived biomarkers further limits risk stratification, antifungal discontinuation decisions, and personalized care.
CONCLUSIONS: Emerging antifungal agents, stewardship strategies, and multidisciplinary care models are essential to improve clinical outcomes and reduce antifungal resistance. This review underscores the need for integrated, team-based diagnostic and therapeutic approaches to close persistent gaps in IC management, ultimately promoting more effective, timely, and individualized care for critically ill patients with Candida spp.
参考来源
- Martin-Loeches I, Cornely OA, Denning DW, et al. Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy. Intensive Care Med. 2025. PMID: 41117944. doi:10.1007/s00134-025-08151-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。